

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



愛帝宮母嬰健康股份有限公司
AIDIGONG MATERNAL & CHILD HEALTH LIMITED

(Incorporated in Bermuda with limited liability)

(Stock code: 286)

INSIDE INFORMATION ANNOUNCEMENT AND CONTINUED SUSPENSION OF TRADING

This announcement is made by Aidigong Maternal & Child Health Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong) (“**SFO**”).

References are made to the announcements of the Company dated 17 January 2025, 5 March 2025, 13 March 2025, 18 March 2025, 30 April 2025 and 27 June 2025 (the “**Announcements**”) in relation to, among others, (i) Ms. Zhu Yufei’s disagreement with Guangdong Wanjia regarding the exercise of shareholders rights in Shenzhen Aidigong and the related litigations; and (ii) the difficulties in allocating the funds generated from the operations of Shenzhen Aidigong due to Ms. Zhu Yufei’s non-cooperation and the ongoing legal proceedings. Unless otherwise defined herein, capitalised terms shall have the same meanings as defined in the Announcements.

LEGAL DISPUTE WITH MS. ZHAO YANHONG

The Company received a writ of summons issued by Ms. Zhao Yanhong (“**Ms. Zhao**”) against the Company as the bond issuer and Mr. Cheung Wai Kuen, a former executive director, chairman and chief executive officer of the Company as the guarantor, in respect of disputes on the repayment of the outstanding amount of a bond issued by the Company (the “**District Court Litigation**”) dated 12 September 2025. Based on the statement of claim of the District Court Litigation, Ms. Zhao claims approximately HKD800,000, interests in relation to the amount and costs.

The principal of the bond is HKD10 million with annual interest rate 7%. As at the date of this announcement, the Company has repaid HKD9.5 million. The Company will make further announcement(s) to update the shareholders and potential investors of the Company when appropriate.

As disclosed in the announcement dated 27 June 2025, as a result of the circumstances disclosed therein, together with the Matters (as defined in the announcement of the Company dated 13 March 2025), the funds generated from the operations of Shenzhen Aidigong cannot be allocated to the Company. The various ongoing litigations have also increased the funding needs. The Company would continue to monitor the situation and adopt measures to mitigate the liquidity position and to improve the Group’s financial position. Meanwhile, the Group has been rigorously defending itself in the Arbitration and taken numerous legal actions to safeguard its legitimate interests in Shenzhen Aidigong.

CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the shares of the Company on The Stock Exchange of Hong Kong Limited has been halted with effect from 9:54 a.m. on 21 February 2025 and will remain suspended until further notice.

Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.

By Order of the Board
Aidigong Maternal & Child Health Limited
Wong Wing Cheung
Company Secretary

Hong Kong, 2 October 2025

As at the date of this announcement, the Board comprises Mr. Huang Wenhua, Mr. Lin Jiang, Mr. Li Runping and Ms. Meng Lijia as executive Directors; and Mr. Chu Pui Ki Dickson and Mr. Wang Bin as independent non-executive Directors.